I-INR ivame ukusetshenziselwa ukukala umphumela wama-anticoagulants omlomo esifweni se-thromboembolic.I-INR ende ibonakala kuma-anticoagulants omlomo, i-DIC, ukuntuleka kwe-vitamin K, i-hyperfibrinolysis njalonjalo.I-INR efushanisiwe ivamise ukubonakala ezimeni ze-hypercoagulable kanye nokuphazamiseka kwe-thrombotic.I-INR, eyaziwa nangokuthi i-International Normalized Ratio, ingenye yezinto zokuhlola umsebenzi we-coagulation.I-INR isuselwe kusisebenzeli se-PT ukuze kulinganiswe Inkomba Yokuzwela Yamazwe Ngamazwe futhi ibale umphumela ngokusebenzisa amafomula ahlobene.Uma i-INR iphezulu kakhulu, kunengozi yokopha okungalawuleki.I-INR ingaqapha ngempumelelo futhi isebenzise umphumela wezidakamizwa ze-anticoagulant.Ngokuvamile, kusetshenziswa i-warfarin yesidakamizwa esilwa ne-anticoagulant, futhi i-INR idinga ukugadwa ngaso sonke isikhathi.Kufanele wazi ukuthi uma kusetshenziswa i-warfarin, i-INR kufanele igadwe njalo.Iziguli ezine-venous thrombosis kufanele ziphuze i-warfarin ngomlomo, futhi inani le-INR kufanele ngokuvamile ligcinwe ku-2.0-2.5.Ezigulini ezine-atrial fibrillation, inani le-inr le-warfarin yomlomo ngokuvamile ligcinwa phakathi kuka-2.0-3.0.Amanani e-INR angaphezu kuka-4.0 angase abangele ukopha okungalawuleki, kuyilapho amanani e-INR angaphansi kuka-2.0 enganikezi i-anticoagulation ephumelelayo.
Ukusikisela: qhubeka uye esibhedlela esivamile ukuze uyohlolwa, futhi ulalele ilungiselelo likadokotela ochwepheshe.
I-Beijing Succeeder ikhethekile kumikhiqizo yokuxilonga i-thrombosis kanye ne-hemostasis ezimakethe zomhlaba.
Njengolunye lwemikhiqizo ehamba phambili emakethe yaseChina yokuxilonga ye-Thrombosis kanye ne-Hemostasis .I-SUCCEEDER ihlangabezane namaqembu e-R&D, Production, Marketing Sales and Service Supplying coagulation analyzers nama-reagents, abahlaziyi begazi le-rheology ESR kanye ne-HCT analyzers platelet aggregation analyzers nge-FDA Cert348 and5 ohlwini.